© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.
October 31st 2022
Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
November 18th 2022
During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers.
This is the first of 2 articles based on this event.